Elacytarabine

Summary

Elacytarabine (CHEMBL2105665) is a phase-3 clinical-stage small molecule; indicated across 4 conditions including acute myeloid leukemia and melanoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 6
• Chemistry: 507.7 Da · C27H45N3O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105665
Name	Elacytarabine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	6438895
Molecular formula	C27H45N3O6
Molecular weight	507.7
InChIKey	FLFGNMFWNBOBGE-FNNZEKJRSA-N

SMILES: CCCCCCCC/C=C/CCCCCCCC(=O)OC[C@@H]1[C@H]([C@@H]([C@@H](O1)N2C=CC(=NC2=O)N)O)O

IUPAC name: [(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl (E)-octadec-9-enoate

Also known as: CP 4055, CP-4055, CP4055, Cytarabine eliadate, Elacitarabina, Elacytarabine, P-4055, ELACYTARABINE

Patent coverage: 92 distinct patent families (206 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
acute myeloid leukemia	3	MONDO:0018874	EFO:0000222
melanoma	2	MONDO:0005105	EFO:0000756
colorectal neoplasm	2	MONDO:0005335	MONDO:0005575
ovarian cancer	1	MONDO:0008170	MONDO:0008170

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE2	3
PHASE1/PHASE2	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01147939	PHASE3	COMPLETED	Study of Elacytarabine Versus Investigator’s Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)
NCT00232726	PHASE2	COMPLETED	Clinical Study of Previously Untreated Patients With Malignant Melanoma
NCT00405743	PHASE1/PHASE2	COMPLETED	A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies
NCT00498407	PHASE2	COMPLETED	A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer
NCT00498836	PHASE2	COMPLETED	Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma
NCT00831636	PHASE1/PHASE2	COMPLETED	A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).